ArticleExpert review of gastroenterology & hepatology2013
Leptin in the treatment of lipodystrophy-associated nonalcoholic fatty liver disease: are we there already?
Article in Expert review of gastroenterology & hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function.F1000Research · 2019Review
- Update on Therapeutic Options in Lipodystrophy.Current diabetes reports · 2018Review
- [Recent advances in serum biomarkers for liver fibrosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2015Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evaluation of: In general, nonalcoholic fatty liver disease (NAFLD) consists of ectopic fat accumulation in the liver, when the ability to store fat in inert reservoirs is overcome. That occurs either when we have an excess of energy/fat such as in obesity, or when adipose tissue is defective, not being able to store even regular amounts of energy, such as in lipodystrophies (LDs). LD associates with metabolic deregulation: insulin resistance/diabetes mellitus and dyslipidemia. Several small studies have shown a beneficial effect of leptin replacement, an adipocyte-derived hormone, in the metabolic profile of patients with LD. The paper under evaluation studied 50 patients with LD-associated NAFLD treated with leptin, suggesting a beneficial effect in liver histology and in decreasing not only steatosis, but also nonalcoholic steatohepatitis, although with no effect on fibrosis after 2 years of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.